Drugs

Unity Bio Restructuring Cuts 30% of Staff, Keeps Focus on Eye Drug

8 days ago   |   By Xconomy

Unity Biotechnology is cutting nearly one third of its staff, a move that comes a month after the biotech's lead drug candidate failed a mid-stage study in osteoarthritis. South San Francisco-based Unity says that the corporate restructuring announced Tuesday should make the cash that it has left last through mid-2022, when data are expected for data the eye drug programs that are now the company's focus. According to Unity's second quarter financial report , the company had $39.6 million in cash and cash equivalents as of June 30. Unity develops treatments for diseases of aging, which the...
Read more ...

 


Search by Tags

   Drugs      Drug      Biotech      BioTech      BioTechnology      National blog main      San Francisco      San Francisco blog main      San Francisco top stories      Anti-Aging      Ascentage Pharma Group      Cancer Drugs      Clinical trials      Diabetic Macular Edema      Diseases of Aging      FDA      Life Sciences      Osteoarthritis      Unity Biotechnology  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Berkeley Team Plays Key Role in Analysis of Particle Interactions That...

Berkeley Team Plays Key Role in Analysis of Particle Interactions That Produce Matter From Light

This image shows a reconstruction of a particle event at CERN's ATLAS detector that produced W bosons from photons, which are particles of light. Researchers at the U.S... Read more ...

Tau-Targeting Alzheimer's Drug from AC Immune, Roche Fails in Phase 2

Tau-Targeting Alzheimer's Drug from AC Immune, Roche Fails in Phase 2

An Alzheimer's disease drug from partners AC Immune and Roche has failed a mid-stage clinical trial, adding another compound to the list of experimental therapies that have... Read more ...

Athira CEO Kawas: Alzheimer's Drug Aims for “Recovery of Brain Function”

Athira CEO Kawas: Alzheimer's Drug Aims for “Recovery of Brain Function”

The key to Athira Pharma's approach to Alzheimer's disease is already inside each of us: a repair mechanism that can regenerate damaged neurons. What's needed to begin the... Read more ...

Gene Therapy Firms Seek Clarity on FDA Exclusivity, Orphan Designations

Gene Therapy Firms Seek Clarity on FDA Exclusivity, Orphan Designations

Gene therapy product developers are seeking more clarity from the US Food and Drug Administration on when viral vectors from the same class will be considered sufficiently... Read more ...

Checkmate, Chromosome 8: The First End-to-End Sequence of a Human Autosome

Checkmate, Chromosome 8: The First End-to-End Sequence of a Human Autosome

Even in the field of genomics where new breakthroughs occur every few months, completion of the first-ever fully sequenced human autosome is a momentous achievement. Highly... Read more ...

Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal

Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal

Grail is set to be acquired for $8 billion by Illumina, the gene sequencing giant that formed the cancer diagnostics developer and spun it out as a separate company four years... Read more ...

Xconomy Awards On-Demand ‘Meet the Finalists' Webcast Series Continues This Week

Xconomy Awards On-Demand ‘Meet the Finalists' Webcast Series Continues This Week

The 2020 National Xconomy Awards complimentary two-week, 11-part, on-demand Meet the Finalists daily webcast series continues this Tuesday and Wednesday at 11 a.m. ET... Read more ...

Knockoff Boosted Tree for Model-Free Variable Selection

AbstractMotivationThe recently proposed knockoff filter is a general framework for controlling the false discovery rate when performing variable selection. This powerful new... Read more ...

IsoResolve: Predicting Splice Isoform Functions by Integrating Gene and...

AbstractMotivationHigh resolution annotation of gene functions is a central goal in functional genomics. A single gene may produce multiple isoforms with different functions... Read more ...

Bedtk: Finding Interval Overlap with Implicit Interval Tree

AbstractSummaryWe present bedtk, a new toolkit for manipulating genomic intervals in the BED format. It supports sorting, merging, intersection, subtraction and the calculation... Read more ...